Congenital hereditary muscular dystrophy
Conditions
Interventions
GIVINOSTAT oral suspension (10 mg/mL) has to be administered orally as 2 oral
doses daily while the subject is in a fed state. The starting dose of
GIVINOSTAT in the present long term study will be
Sponsors
CROMSOURCE BV
Eligibility
Age
2 Years to 64 Years
Inclusion criteria
Inclusion criteria: Subjects must meet all of the following criteria in order to be included in the study: 1. Must have participate in one of the previous study with GIVINOSTAT in DMD and have attended the End of Study Visit or must have been screened in study DSC/14/2357/48 and met: o all the inclusion criteria and none of the exclusion criteria, o had a baseline vastus lateralis muscle fat fraction (VL MFF) assessed by MRS in the range =6 years old 3. Are able to give informed assent and/or consent in writing signed by the subject and/or parent/legal guardian (according to local regulations); 4. Subjects must be willing to use adequate contraception: Contraceptive methods must be used since the previous GIVINOSTAT study through 3 months after the last dose of study drug, and include the following: * True abstinence (absence of any sexual intercourse), when in line with the preferred and usual lifestyle of the subject. Periodic abstinence (e.g. calendar, ovulation, symptothermal, postovulation methods) and withdrawal are not acceptable methods of contraception. * Condom with spermicide and the female partner must use an acceptable method of contraception, such as an oral, transdermal, injectable or implanted steroid-based contraceptive, or a diaphragm or a barrier method of contraception in conjunction with spermicidal jelly such as for example cervical cap with spermicide jelly. GIVINO
Exclusion criteria
Exclusion criteria: Patients who meet any of the following criteria will NOT be eligible for enrolment into the trial: 1. Use of any pharmacologic treatment, other than corticosteroids, that might have had an effect on muscle strength or function within 3 months prior to be enrolled in this study (e.g., growth hormone); Vitamin D, calcium, and any other supplements will be allowed; 2. Use of any current investigational drug other than Givinostat; 3. Have presence of other clinically significant disease, which, in the Investigator*s opinion, could adversely affect the safety of the subject, making it unlikely that the course of treatment or follow-up would be completed, or could impair the assessment of study results; 4. Have a diagnosis of other uncontrolled neurological diseases or presence of relevant uncontrolled somatic disorders that are not related to DMD; 5. Have platelets count, White Blood Cell and Hemoglobin at screening < Lower Limit of Normal (LLN)* (for abnormal screening laboratory test results ( 300 mg/dL (3.42 mmol/L) in fasting condition at screening visit* (for abnormal screening laboratory test results (>ULN), the triglycerides will be repeated once; if the repeat test result is still >ULN, then exclusionary), 7. Have inadequate renal function, as defined by serum Cystatin C >2 x the upper limit of normal (ULN) at screening visit*. If the value is >2 x ULN, the serum Cystatin C will be repeated once; if the repeated test result is still >2 x ULN, the subject should be excluded) 8. Have heart failure (New York Heart Association Class III or IV); 9. Have a current liver disease or impairment, including but not limited to an elevated total bilirubin* (i.e. > 1.5 x ULN), unless secondary to Gilbert disease or pattern consistent with Gilbert's; 10. Have a baseline QTcF >450 msec, (as the mean of 3 consecutive readings 5 minutes apart) or history of additional risk factors for torsades de pointes (e.g., heart failure, hypokalemia, or family history of long QT syndrome); 11. Have a psychiatric illness/social situations rendering the potential subject unable to understand and comply with the muscle function tests and/or with the study protocol procedures. 12. Have any hypersensitivity to the components of study medication; 13. Have a sorbitol intolerance or sorbitol malabsorption, or have the hereditary form of fructose intolerance.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Type, incidence, and severity of treatment related/not related AEs and SAEs (Baseline through week 48 and then yearly till the end of the study) | — |
Secondary
| Measure | Time frame |
|---|---|
| For ambulant patients: • Change from baseline in physical function as measured by 6MWT, NSAA, Time function tests (e.g. time to rise from floor, time to climb 4-stairs, time to 10m walk)(week 48 and then yearly till the end of the study) • Change from baseline in muscle strength (e.g. knee extension and elbow flexion) as measured by HHM (week 48 and then yearly till the end of the study) For non-ambulant patients: • Change in physical function from baseline in the Egen Klassifikation (EK) score (week 48 and then yearly till the end of the study) • Change in patient and/or parent/caregiver reports of activities of daily living as measured by Barthel Index (week 48 and then yearly till the end of the study • Change in upper limbs muscle strength (week 48 and then yearly till the end of the study) evaluated by handheld myometry (HHM) For all patients: • Change from baseline in physical function as measured by the Performance of Upper Limb (PUL) and MFM (week 48 and then yearly till the end of the study) • Change from baseline in respiratory function (week 48 and then yearly till the end of the study) (e.g. FVC, FEV1, PEF) • Change in patient and/or parent/caregiver reports of quality of life as measured by PedsQL for paediatric patients and by SF-36 for adults patients (week 48 and then yearly till the end of the study), • Age at major disease milestones (e.g. age at loss of ambulation, age at respiratory support needed during the day, age at scoliosis surgery, age at death). In addition to the declared time points, the statistical analysis will be performed every year of treatment till the MA will be granted. Exploratory Endpoints: • Comparison between the results of the *delayed GIVINOSTAT group* (i.e. all patients in placebo group during the Study DSC/14/2357/48 or Study DSC/14/2357/50 which will be switched to GIVINOSTAT in this study) and the results of the *GIVINOSTAT group* (i.e., the patients already treated with GIVINOSTAT in St | — |
Countries
Netherlands
Outcome results
None listed